Core Viewpoint - Enlivex Therapeutics reported significant profitability in 2025, primarily driven by the appreciation of its treasury assets linked to decentralized prediction markets, particularly through the RAIN token Financial Performance - Enlivex generated a net income of $1.23 billion for the full year 2025, with diluted earnings per share (EPS) of $25.48, calculated in accordance with GAAP [3][7] - The company ended 2025 with $2.31 billion in total treasury and treasury-related assets and $1.93 billion in shareholders' equity, attributed to market-based revaluation of these assets [2][4] Treasury Strategy - The company has adopted a "dual-engine" strategy combining clinical-stage drug development with a digital-asset treasury focused on decentralized prediction markets [4] - Enlivex is building a digital-asset treasury around the RAIN token, holding an exclusive option to buy up to 275 billion RAIN at $0.0033 per token, with a planned purchase of 3 billion RAIN for $10 million [6][11] - The treasury strategy is centered on RAIN, which is viewed as a decentralized protocol with increasing trading volumes and institutional engagement [8][9] Clinical Development - Enlivex's lead product, Allocetra, has received FDA clearance for a Phase IIb trial in knee osteoarthritis, with expected topline data in 2027 [5][14] - The company emphasizes the clinical platform's importance for long-term value, with Allocetra showing meaningful improvements in pain and function for osteoarthritis patients [13][15] Market Position and Future Outlook - Management noted that the market capitalization is currently trading at a discount to its treasury valuation, which they hope to address through growth in the prediction market ecosystem [16] - Enlivex aims to potentially self-fund its clinical development through a small percentage of treasury asset appreciation, allowing investors to benefit from both clinical and treasury sides [17][19]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting significant appreciation in treasury and treasury-related assets [3][11] - The company ended the year with $2.31 billion in total treasury and treasury-related assets and $1.93 billion in shareholders' equity, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The clinical platform, particularly Allocetra, has shown clinically meaningful and statistically significant results, with a favorable safety profile, advancing towards late-stage development in osteoarthritis and other inflammatory indications [9][15] - The treasury strategy is designed to capture value from the emerging prediction markets economy, which is expected to grow significantly [4][12] Market Data and Key Metrics Changes - The prediction markets ecosystem is evolving, with increasing trading volumes and institutional engagement, positioning the company to capture early structural momentum [4][12] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growth of decentralized prediction markets, enhancing long-term shareholder value [13][14] Company Strategy and Development Direction - The company is focused on a dual-engine model that integrates clinical development with a treasury strategy aligned with the growth of prediction markets [3][10] - The strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][7] Management's Comments on Operating Environment and Future Outlook - Management believes that the current results are not isolated but represent the beginning of a broader shift towards institutional adoption of prediction markets [24] - The company aims to continue scaling its treasury strategy and advancing clinical programs, with a focus on capturing value across both scientific innovation and financial infrastructure [17][28] Other Important Information - The company announced a $21 million debt financing agreement to fund clinical development and acquire additional RAIN tokens at a discount [7][8] - A share repurchase program was approved to acquire up to $20 million of outstanding ordinary shares, indicating confidence in the company's value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - Management attributed the profits to the bullish market for prediction markets, specifically the RAIN token, which increased in value [20] Question: How to explain the market cap discount to treasury valuation? - Management noted that the overall crypto market has been out of favor, leading to net asset value discounts, but expects this to improve as the prediction market ecosystem grows [21] Question: Does this change how clinical-stage companies can be financed? - Management indicated that the funding landscape has changed, with earlier-stage biotech companies facing challenges, but Enlivex's model allows for self-funding through treasury asset appreciation [22][23] Question: Is this a one-off outcome or the beginning of a broader shift? - Management sees this as the beginning of a broader shift towards public companies providing exposure to prediction markets [24] Question: How should investors view Enlivex after these results? - Management believes investors will now pay more attention to both sides of the dual model strategy following the earnings report [26] Question: What are the key drivers for scaling this model? - Management identified the growth of the prediction markets ecosystem and the advancement of the clinical program as key drivers for scalability [27]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting a significant appreciation in treasury and treasury-related assets [3][11] - The total treasury and treasury-related assets reached $2.31 billion, with shareholders' equity at $1.93 billion, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The company operates a dual-engine model combining clinical development with a treasury strategy focused on prediction markets, which is expected to drive long-term value [3][10] - The clinical platform, particularly Allocetra, has shown clinically meaningful results and is advancing towards late-stage development in osteoarthritis, with FDA clearance for a phase IIb trial [9][15] Market Data and Key Metrics Changes - The prediction markets ecosystem is experiencing structural momentum, with increasing trading volumes and institutional engagement, positioning the company to capture early opportunities [12][14] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growth of decentralized prediction markets, enhancing long-term shareholder value [13][14] Company Strategy and Development Direction - The company aims to establish itself as a leader in a new category of public companies that integrate scientific innovation with financial infrastructure [10][17] - A strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][8] Management's Comments on Operating Environment and Future Outlook - Management believes the current results are indicative of a broader shift towards institutional adoption of prediction markets, with expectations for continued growth in this sector [24][27] - The company is focused on scaling its treasury strategy and advancing clinical programs, with a commitment to leading the convergence of biology and finance [17][28] Other Important Information - The company announced a $21 million debt financing agreement to support clinical development and acquire additional RAIN tokens [7][8] - A share repurchase program was approved to acquire up to $20 million of outstanding shares, reflecting confidence in the company's value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - Management attributed the profits to the bullish market for prediction markets, specifically the RAIN token, which increased in value [20] Question: How to explain the market cap discount to treasury valuation? - Management noted that the overall crypto market is out of favor, leading to net asset value discounts, but expects this to improve as the prediction market ecosystem grows [21] Question: Does this change how clinical-stage companies can be financed? - Management indicated that the funding landscape has shifted, with earlier-stage biotech companies facing challenges, but Enlivex's model allows for self-funding through treasury asset appreciation [22][23] Question: Is this a one-off outcome or the beginning of a broader shift? - Management sees this as the beginning of a broader shift towards public companies providing exposure to prediction markets [24] Question: How should investors think about Enlivex after these results? - Management believes investors will now pay more attention to the dual model strategy following the earnings report [26] Question: What are the key drivers for scaling this model? - Management identified the growth of the prediction markets ecosystem and the success of the clinical program as key drivers for scalability [27]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting a significant appreciation in treasury and treasury-related assets [3][11] - The total treasury and treasury-related assets reached $2.31 billion, with shareholders' equity at $1.93 billion, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The company's dual-engine model integrates clinical development with a treasury strategy focused on prediction markets, which is expected to drive long-term value [3][10] - The clinical platform, particularly Allocetra, has shown statistically significant results and a favorable safety profile, with a clear pathway toward late-stage development in osteoarthritis [9][16] Market Data and Key Metrics Changes - The prediction markets ecosystem is experiencing structural momentum, with increasing trading volumes and institutional engagement, positioning the company to capture early opportunities [12][18] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growing decentralized prediction markets, enhancing long-term shareholder value [13][15] Company Strategy and Development Direction - The company aims to establish itself as a leader in a new category of public companies that combine scientific innovation with emerging financial infrastructure [10][18] - A strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][8] Management's Comments on Operating Environment and Future Outlook - Management believes that the prediction markets will continue to evolve into a core layer of global financial infrastructure, validating the company's treasury strategy [4][12] - The company is optimistic about the scalability of its dual-engine model, driven by the growth of both prediction markets and its clinical programs [30][31] Other Important Information - The company announced a $21 million debt financing agreement to fund clinical development and acquire additional RAIN tokens at a discount [6][7] - A share repurchase program was approved to acquire up to $20 million of outstanding shares, reflecting confidence in the company's long-term value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - The company's exposure to prediction markets, particularly the RAIN token, has led to significant valuation increases, contrasting with broader crypto market trends [20][22] Question: How to explain the market cap discount to treasury valuation? - The current market sentiment towards crypto has led to net asset value discounts, but there is hope for recovery as the prediction market ecosystem grows [23] Question: Does this change how clinical-stage companies can be financed? - The funding landscape for early-stage biotech has become more challenging, but Enlivex's model allows for self-funding through treasury asset appreciation, mitigating dilution concerns [24][25] Question: Is this a one-off outcome for prediction markets in public company earnings? - Management views this as the beginning of a broader shift towards integrating prediction markets into public company structures [26] Question: How should investors view Enlivex after these results? - Investors are likely to reassess the company's value proposition, recognizing the potential of its dual model strategy [29] Question: What are the key drivers for scaling this model? - The scalability will depend on the growth of the prediction markets ecosystem and the success of the clinical programs, with several milestones planned for the next two years [30]

Core Insights - Enlivex Therapeutics Ltd. will host a virtual fireside chat on December 11, 2025, to discuss its recent $212 million private placement and future plans [1][2][3] - The company is focusing on advancing the clinical development of Allocetra™, a therapy for osteoarthritis, which affects over 32.5 million Americans and 300 million people globally [5] Company Plans - Shai Novik, Executive Chairman, will provide updates on the digital asset treasury strategy centered around RAIN token accumulation [2] - Enlivex aims to offer investors exposure to RAIN as a primary treasury reserve asset [4] Clinical Development - Allocetra™ is designed to treat osteoarthritis, a prevalent joint disease with significant hospitalization rates in the U.S. [5] - There are currently no FDA or EMA approved medications that can halt or reverse joint damage in osteoarthritis patients [5]

Core Insights - Enlivex has implemented the world's first RAIN prediction markets token digital asset treasury strategy through RAIN token accumulation [1][3][7] - The company is focused on the clinical development of Allocetra, a novel therapy for knee osteoarthritis, addressing a significant unmet medical need in a growing market [2][8] Company Developments - Enlivex has closed a $212 million private investment, with plans to utilize the proceeds for the RAIN prediction markets token treasury strategy while maintaining its core business operations [3][7] - Former Italian Prime Minister Matteo Renzi has joined the Board of Directors, emphasizing the importance of responsible innovation and the potential of blockchain technologies [5] RAIN Protocol Overview - RAIN is a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade custom options on various markets [4] - The protocol features a deflationary Buyback & Burn mechanism and aims to be a leading platform for prediction markets, promoting transparency and community participation [4] Market Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million people globally, with a projected increase to 78 million Americans by 2040 [8] - There are currently no FDA or EMA approved medications that can effectively halt or reverse the progression of joint damage in osteoarthritis patients, highlighting a critical need for effective treatments [8]

Core Insights - Enlivex Therapeutics is raising $212 million in a private placement to become the first publicly traded U.S. company to adopt a blockchain-based prediction markets token, RAIN, as its main treasury reserve asset [1][3] - The RAIN token operates on the Arbitrum blockchain, enabling users to create and trade prediction markets on real-world events [1][2] - Enlivex plans to use the majority of the funds raised to purchase RAIN tokens, viewing the prediction markets space as a strategic growth area [3] Company Developments - Enlivex has a market cap of $22 million on Nasdaq and aims to integrate RAIN tokens into its treasury management strategy [3] - The company is continuing clinical trials for its lead drug candidate, Allocetra, which targets osteoarthritis, a condition affecting over 30 million Americans [4] - Matteo Renzi, former Prime Minister of Italy, is expected to join Enlivex's board following the completion of the deal on November 25 [5] Financial Aspects - The transaction is priced at $1 per share, representing an 11.5% premium over Enlivex's last trading price [5] - Last year, Enlivex's board approved the purchase of up to $1 million in Bitcoin as part of its cash-management strategy [5]

Core Insights - Enlivex Therapeutics Ltd. announced a private investment in public equity (PIPE) of 212 million shares at $1.00 per share, representing an 11.5% premium from the previous closing price, expecting gross proceeds of approximately $212 million [1] - The proceeds will be used to implement the first RAIN prediction markets token treasury strategy while maintaining focus on core business operations [2] - Enlivex aims to become the first U.S.-traded public company providing investors exposure to prediction markets following the transaction [4] Financial Details - The PIPE transaction involves 212 million shares priced at $1.00 each, totaling around $212 million in gross proceeds [1] - The funding will be a combination of USD and USDT [1] Business Strategy - Enlivex will utilize the PIPE proceeds to support the RAIN protocol, a decentralized predictions and options platform built on the Arbitrum network [2][3] - RAIN allows users to create and trade custom options on any market, governed by the RAIN token with a deflationary Buyback & Burn mechanism [3] Clinical Development - Enlivex is focused on the late-stage clinical development of Allocetra, a therapy for osteoarthritis, which affects over 32.5 million Americans and more than 300 million people globally [5] - Recent data from the Phase 2a trial of Allocetra showed significant pain reduction and functional improvement in patients with moderate to severe knee osteoarthritis at 6 months [6] Trial Results - Allocetra demonstrated a statistically significant improvement in pain and function at 3 months and 6 months in patients aged 60 and above, with reductions of -26.8 points and -27.8 points respectively compared to placebo [7]